[Edaily Reporter NA EUN-KYUNG ] #SEERS Technology, a wearable artificial intelligence (AI) diagnostics and monitoring company, announced on the 13th that it recorded consolidated revenue of 60.9 billion won and operating profit of 26.8 billion won in the first half of 2026, surpassing its full-year results from last year. Compared to the same period last year, revenue increased by 407% and operating profit by 2,888%.

Second-quarter revenue totaled 28.4 billion won, with operating profit at 13.0 billion won. As the company expanded its business primarily at top-tier general hospitals—including the “Big 5”—some revenue from large hospitals with relatively long contract periods was deferred to the second half of the year, and overseas project schedules were partially adjusted due to geopolitical factors in the Middle East.

However, thanks to improved platform operational efficiency and enhanced cost competitiveness, the second-quarter operating profit margin reached 45.6%, up 3.0 percentage points from the previous quarter’s 42.6%. This marks the highest quarterly operating profit margin in the company’s history.

First-half performance has already surpassed last year’s full-year results. Last year, SEERS Technology’s annual revenue and operating profit were 48.2 billion won and 16.3 billion won, respectively. First-half revenue this year is 26.3% higher than last year’s full-year figure, while operating profit is up 64.4%. The company explained that economies of scale resulting from the expansion of its platform business and improvements in production and operational efficiency have led to improved profitability.

This earnings growth was driven by “thynC,” an AI-based inpatient monitoring platform. thynC’s second-quarter revenue was 26.8 billion won, and its cumulative revenue for the first half reached 58.0 billion won, accounting for approximately 95% of total first-half revenue. thynC has expanded its customer base to major tertiary hospitals, including Seoul National University Hospital, Asan Medical Center, and Samsung Medical Center, and has gained experience operating approximately 20,000 hospital beds across 220 medical institutions nationwide.

The company plans to expand its customer base to hospital-level medical institutions and long-term care hospitals in the second half of the year. It expects the number of installed beds and related revenue to increase starting in the third quarter, as installations for orders carried over from the second quarter and new contract beds are concentrated during this period.

“mobiCARE,” the company’s wearable AI ECG analysis solution, recorded sales of 1.5 billion won in the second quarter and cumulative sales of 2.8 billion won for the first half of the year. First-half sales increased by 29% compared to the same period last year. In addition to demand for examinations centered on cardiology, the company is expanding the solution’s scope of use to include health screening services and expects related sales to increase starting in the third quarter, when demand for health screenings typically rises.

The company also plans to expand its overseas business starting in the second half of the year. Although the schedules for some projects were adjusted due to geopolitical uncertainties in the Middle East during the second quarter, the company plans to pursue its U.S. business based on its U.S. Food and Drug Administration (FDA) marketing authorization while also launching its operations in the United Arab Emirates (UAE) in earnest.

Lee Young-shin, CEO of SEERS Technology, stated, “The first half of the year proved that SEERS’ platform business model can generate both growth and profitability.” He added, “In the second half, we will expand our domestic business scope to include hospitals and long-term care facilities, and fully launch our operations in the UAE and the U.S. to demonstrate the success of our AI medical platform’s growth model—which has been validated in Korea—in the global market as well.”